Vidhi Specialty Food FY26 Net Profit Rises 10.80%; Capex Plans and New Product Lines in Focus
Vidhi Specialty Food Ingredients Limited reported FY26 net profit of INR49.15 crores, up 10.80% YoY, with EBITDA improving to INR78 crores and margins expanding to 20.52% despite flat revenues of INR380 crores. The company outlined capex of INR75–85 crores for new high-margin product lines at Dahej, with commissioning expected in the middle of FY28, while its CoatIcon pharma coating range advances through customer qualification stages.

*this image is generated using AI for illustrative purposes only.
Vidhi Specialty Food Ingredients Limited held its Q4 and FY26 Earnings Conference Call on May 14, 2026, with Chairman and Managing Director Bipin Manek, Joint Managing Director Mihir Manek, and Chief Financial Officer Mitesh Manek presenting the company's audited financial results for the year ended March 31, 2026. The management highlighted resilient performance despite significant global economic uncertainty, geopolitical tensions, tariff pressures, and a slowdown in demand across several international markets.
Financial Performance
The company reported revenue from operations of INR380 crores for FY26, compared to INR382.30 crores in FY25. Despite subdued demand in certain international markets during the first half of the year, disciplined cost management and product mix optimization enabled the company to deliver strong profitability. The following table summarises key financial metrics:
| Metric | FY26 | FY25 |
|---|---|---|
| Revenue from Operations | INR380 crores | INR382.30 crores |
| EBITDA | INR78 crores | INR68 crores |
| EBITDA Margin | 20.52% | 17.91% |
| Profit Before Tax | INR65.97 crores | INR60.16 crores |
| Net Profit | INR49.15 crores | INR44.35 crores |
| Net Profit Margin | 12.93% | 11.66% |
| Operating Profit Margin | 21.01% | 18.75% |
| Profit Before Tax Margin | 17.36% | 16.10% |
Net profit grew 10.80% year-on-year to INR49.15 crores, while EBITDA margins expanded from 17.91% to 20.52%, supported by better realizations, increased contribution from specialty and high-margin products, improved manufacturing efficiencies, and tighter cost management. The CFO noted that manufacturing sales for FY26 stood at INR330 crores, with the effective EBITDA margin on manufactured sales close to 24%–25%.
Balance Sheet and Key Ratios
The company maintained a strong and conservative balance sheet. The debt-to-equity ratio remained low at 0.28%, reflecting prudent fiscal management. Key operational and return ratios are presented below:
| Ratio | FY26 | FY25 |
|---|---|---|
| Debt-to-Equity Ratio | 0.28% | — |
| Return on Capital Employed | 20.90% | 20.17% |
| Return on Equity | 14.94% | 14.92% |
| Debtors Turnover Ratio | 2.66% | 2.91% |
| Inventory Turnover Ratio | 4.70% | 4.99% |
| Current Ratio | 3.91% | 2.92% |
| Interest Coverage Ratio | 16.75% | 28.27% |
The CFO noted that the decline in the interest coverage ratio was attributable to the withdrawal of the subvention scheme on export finance by the Indian government as of December 2025, which led to a slight increase in finance costs.
Operational Highlights and Export Markets
Management stated that demand conditions remained subdued in certain international markets during the first half of FY26 but improved subsequently. The company expects full utilization of both its Dahej and Roha facilities in the current financial year. On export markets, the management clarified that exports to North America (comprising the U.S., Canada, and Mexico) account for 19% of total exports. Mihir Manek noted that while the U.S. market has stabilised following tariff-related disruptions, additional growth is expected from emerging markets as geopolitical conditions ease. Customer inventory levels in the U.S. had reduced by approximately 50% during the period of elevated tariffs as customers drew down existing stocks. The management also addressed concerns around synthetic food color regulations in the U.S., clarifying that all exported color ranges are approved by the U.S. FDA and that each batch undergoes testing at the FDA's Washington laboratory before being cleared for use.
Strategic Initiatives and Capital Expenditure
The company is advancing its CoatIcon range of tablet coating systems, currently in aggressive sampling and customer qualification stages with several pharmaceutical companies in India and international markets. The typical customer approval cycle for this product is approximately 6 months due to stability testing requirements. The contribution of high-value, high-margin products to the total product portfolio currently stands at approximately 5%, with management expecting this to rise to 10%–12% or higher in FY27. Key capital expenditure details are summarised below:
| Initiative | Details |
|---|---|
| CoatIcon Pharma Coating (Scale-up) | INR5 crores to INR12 crores |
| New Product Lines – Phase 1 Capex | INR75 crores to INR85 crores |
| Expected Capex Deployment | Largely in FY27 |
| Commissioning Timeline | Middle of FY28 (18 months) |
| Expected Phase 1 Revenue Potential | INR125 crores to INR150 crores |
| Facility | Dahej |
The new product lines under development are described as having a very high margin profile with thin to negligible competition. The company has two R&D facilities on the outskirts of Mumbai, employing in excess of 60 dedicated chemists, and has invested in excess of INR4.5 crores to INR5 crores in analytical equipment at these facilities. Management also noted a one-off increase in other expenses during the quarter, partly attributable to R&D costs and U.S. FDA certification costs of $1 per kilogram, which are to be passed on to customers upon sale of the relevant products.
Historical Stock Returns for Vidhi Specialty Food Ingredients
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.36% | +1.14% | -8.52% | -22.01% | -34.45% | +39.41% |
How quickly could Vidhi Specialty's new high-margin product lines ramp up to meaningful revenue contribution beyond the projected INR125–150 crores, and what competitive risks could emerge once these 'negligible competition' products gain market visibility?
Given that North America accounts for 19% of exports and U.S. customer inventory levels dropped ~50% during tariff disruptions, how vulnerable is Vidhi's revenue trajectory to any re-escalation of U.S.-India trade tensions or new tariff regimes?
With the CoatIcon pharma coating range currently at only 5% of the portfolio and targeting 10–12% by FY27, what is the realistic addressable market size in India and internationally, and which competing tablet coating suppliers pose the greatest threat to customer adoption?


































